MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

87.95 0.38

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

87.14

Max

90.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	5.4M -48M
Verkäufe	6M 57M
Gewinnspanne	-82.974
Angestellte	414
EBITDA	5.1M -43M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+56.18% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-502M 5.9B
Vorheriger Eröffnungskurs	87.57
Vorheriger Schlusskurs	87.95

Nachrichtenstimmung

By Acuity

26%

74%

75 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

60 / 65.58 Unterstützung & Widerstand

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Apr. 2026, 23:26 UTC

Heiße Aktien

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. Apr. 2026, 20:41 UTC

Wichtige Markttreiber

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. Apr. 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. Apr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. Apr. 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. Apr. 2026, 22:08 UTC

Ergebnisse

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Health Care Roundup: Market Talk

16. Apr. 2026, 20:49 UTC

Ergebnisse

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. Apr. 2026, 20:43 UTC

Ergebnisse

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Netflix Says Engagement Quality Hits New High -- Market Talk

16. Apr. 2026, 20:30 UTC

Heiße Aktien

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. Apr. 2026, 20:25 UTC

Ergebnisse

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:23 UTC

Ergebnisse

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. Apr. 2026, 20:19 UTC

Ergebnisse

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

56.18% Vorteil

12-Monats-Prognose

Durchschnitt 137.14 USD 56.18%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

75 / 348 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.